|
| Exchange Received Time 21/03/2017 08:45:31 Exchange Disseminated Time 21/03/2017 08:45:32 Time Taken 00:00:01 | | Sub: Disclosure under Regulation 30(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended The Board of Directors of Jubilant Pharma Limited ('JPL'), a material wholly owned subsidiary of the Company in Singapore, has approved to negotiate a potential acquisition of a specialty pharma business in the United States using only internal accruals, , subject to due diligence, satisfactory agreements, etc. and its final approval. The proposed acquisition is a niche, profitable speciality pharma business with a strategic fit and is expected to provide competitive edge for JPL's existing business, if it materialises. |
|
|